Latest News and Press Releases

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing...

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative...

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning...

Boca Raton, FL, May 29, 2026 (GLOBE NEWSWIRE) -- Motivosity, a leading employee recognition and rewards platform focused on building connected workplace cultures, today announced it has been...

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options If you purchased or...

Austin, United States, May 28, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, The Drug Delivery Devices Market size was valued at USD 453.53 Billion in 2025 and is projected to reach USD 949.21...

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning...

MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS

GLEN ALLEN, VA, May 27, 2026 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device combinations and auto-injector innovation and the makers of the only epinephrine auto-injector with...